| 查看: 572 | 回复: 5 | |||
| 当前主题已经存档。 | |||
[交流]
FDA马上就要批准的新药
|
|||
|
Nuvigil Cephalon Receives Approvable Letter for Nuvigil (armodafinil) FRAZER, Pa., May 1, 2006 -- Cephalon, Inc. announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Nuvigil (armodafinil) Tablets. The company submitted a new drug application (NDA) on March 31, 2005, seeking to market Nuvigil for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome (OSA/HS) and shift work sleep disorder (SWSD). FDA approval of Nuvigil is contingent upon finalizing the product label. "We are working closely with the FDA to move this application to an approval and expand our offering of wake-promotion choices for patients," said Dr. Paul Blake, Executive Vice President, Worldwide Medical and Regulatory Operations. "Based on the clinical trials, Nuvigil demonstrated a long duration of effect throughout the waking hours and we are excited at the potential to offer broader options to meet the needs of patients and physicians seeking treatment for excessive sleepiness." Armodafinil is a single-isomer formulation of modafinil, the active pharmaceutical ingredient contained in Provigil (modafinil) Tablets [C-IV]. Cephalon submitted data from four double-blind, randomized, placebo-controlled studies of Nuvigil in patients with excessive sleepiness associated with either narcolepsy, OSA/HS or SWSD to FDA for evaluation as part of the NDA. In these studies, Nuvigil was generally well tolerated, with a safety profile consistent with that observed in studies of Provigil. The most common adverse effects observed included headache, nausea, dizziness, insomnia and anxiety. As previously announced, the company submitted additional information to the FDA related to a possible case of Stevens Johnson Syndrome associated with its Sparlon (modafinil) application. In its Nuvigil approvable letter, the FDA indicated that the outcome of its review of this new information will be addressed directly in the label for Nuvigil. About Excessive Sleepiness (Hypersomnolence) Excessive sleepiness, medically known as hypersomnolence, is the primary symptom -- and often the most debilitating feature -- experienced by the millions of Americans who suffer from narcolepsy, OSA/HS, and SWSD. Despite this fact, it is estimated that 50 to 90 percent of the time, health care professionals fail to recognize that these patients are suffering from excessive sleepiness. The defining characteristic of excessive sleepiness is a consistent inability to stay awake and alert enough to safely and successfully accomplish tasks of daily living. Persons experiencing excessive sleepiness who seek medical attention typically complain of fatigue, tiredness, lapses of attention, lack of energy, low motivation, difficulty concentrating, disrupted sleep, snoring or difficulties at work. |
回复此楼» 猜你喜欢
华理药学学硕求调剂，总分324
已经有0人回复
-
澳门理工大学人工智能药物发现中心招收2026级博士研究生（申请-考核制）
已经有10人回复
-
药物学论文润色/翻译怎么收费?
已经有282人回复
-
中国医药行业发展现状：标准品推动药品检测水平提升
已经有1人回复
-
标准品的纯度对于药品质量的影响有多大？
已经有0人回复
-
如何制备符合技术要求的药品标准品？
已经有0人回复
-
对照品在药品研发中的不可或缺性
已经有0人回复
-
标准品的分类和用途，你知道多少？
已经有0人回复
-
杂质对照品价格如何界定和正确使用方法
已经有0人回复
WFB1966
主管区长
0.5
2楼2006-05-14 11:44:59
3楼2006-05-14 14:04:36
4楼2006-05-16 10:25:58
notallwrong
实习版主
0.5
| 谢谢分享，赞 |
5楼2006-05-16 10:30:55
6楼2006-05-18 16:52:43
